Edgestream Partners, L.P. Nuvalent, Inc. Transaction History
Edgestream Partners, L.P.
- $2.29 Billion
- Q4 2024
A detailed history of Edgestream Partners, L.P. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 11,724 shares of NUVL stock, worth $931,940. This represents 0.04% of its overall portfolio holdings.
Number of Shares
11,724
Previous 2,829
314.42%
Holding current value
$931,940
Previous $289,000
217.3%
% of portfolio
0.04%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding NUVL
# of Institutions
231Shares Held
58.9MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.43 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$426 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$358 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$240 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$208 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.42B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...